Results 41 to 50 of about 47,637 (238)

The serotonin transporter promotes a pathological estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 1B1 pulmonary circulation [PDF]

open access: yes, 2016
Pulmonary arterial hypertension (PAH) is a devastating vasculopathy that predominates in women and has been associated with dysregulated estrogen and serotonin signaling. Overexpression of the serotonin transporter (SERT+) in mice results in an estrogen-
Anagnostopoulou, Aikaterini   +9 more
core   +1 more source

Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4.

open access: yesPLoS ONE, 2020
BACKGROUND:The knowledge of hereditary predisposition has changed our understanding of Pulmonary Arterial Hypertension. Genetic testing has been widely extended and the application of Pulmonary Arterial Hypertension specific gene panels has allowed its ...
Ignacio Hernandez-Gonzalez   +15 more
doaj   +1 more source

Application of [18F]FLT‐PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers

open access: yesPulmonary Circulation, 2021
Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Liza Botros   +11 more
doaj   +1 more source

Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival [PDF]

open access: yes, 2017
In pulmonary hypertension (PH), right ventricular (RV) performance determines survival. Pulmonary artery (PA) stiffening is an important biomechanical event in PH and also predicts survival based on the PA relative area change (RAC) measured at rest ...
Bellofiore, Alessandro   +6 more
core   +1 more source

Platelet‐Derived Growth Factor Receptor Type α Activation Drives Pulmonary Vascular Remodeling Via Progenitor Cell Proliferation and Induces Pulmonary Hypertension

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Platelet‐derived growth factor is a major regulator of the vascular remodeling associated with pulmonary arterial hypertension. We previously showed that protein widely 1 (PW1+) vascular progenitor cells participate in early vessel ...
Julien Solinc   +19 more
doaj   +1 more source

“Nocturnal Seizures” in Idiopathic Pulmonary Arterial Hypertension [PDF]

open access: yesJournal of Clinical Sleep Medicine, 2013
The usual differential diagnoses of nocturnal events in children include parasomnias, nocturnal seizures, nocturnal reflux (Sandifer syndrome), hypnic jerks, periodic limb movements of sleep, and sleep disordered breathing. We report a previously healthy young girl who presented to the sleep clinic for evaluation of nocturnal events which were ...
Anthony, Izzo   +4 more
openaire   +2 more sources

Proceedings: Regenerative Medicine for Lung Diseases: A CIRM Workshop Report. [PDF]

open access: yes, 2017
The mission of the California Institute of Regenerative Medicine (CIRM) is to accelerate treatments to patients with unmet medical needs. In September 2016, CIRM sponsored a workshop held at the University of California, Los Angeles, to discuss ...
DeWitt, Natalie D   +2 more
core   +1 more source

Nocturnal hypoxia in patients with idiopathic pulmonary arterial hypertension [PDF]

open access: yesPulmonary Circulation, 2020
BackgroundSleep‐disordered breathing causes a variety of cardiovascular complications and increases the risk of a poor prognosis in patients. There is still some controversy regarding the clinical diagnosis and treatment of sleep‐disordered breathing in patients with pulmonary hypertension.
Lu Yan   +6 more
openaire   +4 more sources

A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out? [PDF]

open access: yesТерапевтический архив, 2017
The paper considers a clinical example of current therapy for idiopathic pulmonary arterial hypertension in a female patient with its clinical deterioration.
N A Tsareva, S N Avdeev, G V Neklyudova
doaj   +1 more source

MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]

open access: yes, 2020
Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang   +22 more
core   +1 more source

Home - About - Disclaimer - Privacy